Analysis Novo Nordisk’s Balancing Act: A Failed Heart Study, a Legal Win, and a Quiet Bet on Smaller Doses
The Danish pharmaceutical giant is navigating one of its most consequential stretches in years, juggling a clinical setback, a courtroom victory, and a strategic recalibration of its blockbuster obesity franchise....